Literature DB >> 27322358

Transmission pathways and mediators as the basis for clinical pharmacology of pain.

Daniel R Kirkpatrick1, Dan M McEntire1, Tyler A Smith1, Nicholas P Dueck1, Mitchell J Kerfeld1, Zakary J Hambsch1, Taylor J Nelson1, Mark D Reisbig1, Devendra K Agrawal1.   

Abstract

INTRODUCTION: Mediators in pain transmission are the targets of a multitude of different analgesic pharmaceuticals. This review explores the most significant mediators of pain transmission as well as the pharmaceuticals that act on them. Areas covered: The review explores many of the key mediators of pain transmission. In doing so, this review uncovers important areas for further research. It also highlights agents with potential for producing novel analgesics, probes important interactions between pain transmission pathways that could contribute to synergistic analgesia, and emphasizes transmission factors that participate in transforming acute injury into chronic pain. Expert commentary: This review examines current pain research, particularly in the context of identifying novel analgesics, highlighting interactions between analgesic transmission pathways, and discussing factors that may contribute to the development of chronic pain after an acute injury.

Entities:  

Keywords:  Analgesia; analgesic synergy; anesthesia; cannabinoids; novel analgesics; opioids; pain; pain chronicity; pain transmission

Year:  2016        PMID: 27322358      PMCID: PMC5215101          DOI: 10.1080/17512433.2016.1204231

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  189 in total

1.  G-protein-coupled receptor heterodimerization modulates receptor function.

Authors:  B A Jordan; L A Devi
Journal:  Nature       Date:  1999-06-17       Impact factor: 49.962

2.  Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice.

Authors:  J I Mobarakeh; S Sakurada; S Katsuyama; M Kutsuwa; A Kuramasu; Z Y Lin; T Watanabe; Y Hashimoto; T Watanabe; K Yanai
Journal:  Eur J Pharmacol       Date:  2000-03-10       Impact factor: 4.432

3.  Facilitative interactions between vasoactive intestinal polypeptide and receptor type-selective opioids: implications for sensory afferent regulation of spinal opioid action.

Authors:  Nai Jiang Liu; Alan R Gintzler
Journal:  Brain Res       Date:  2003-01-03       Impact factor: 3.252

4.  Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor.

Authors:  P Naveilhan; H Hassani; G Lucas; K H Blakeman; J X Hao; X J Xu; Z Wiesenfeld-Hallin; P Thorén; P Ernfors
Journal:  Nature       Date:  2001-01-25       Impact factor: 49.962

5.  Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain.

Authors:  M I Gonzalez; M J Field; J Hughes; L Singh
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

6.  Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy.

Authors:  D J Goldstein; O Wang; B D Gitter; S Iyengar
Journal:  Clin Neuropharmacol       Date:  2001 Jan-Feb       Impact factor: 1.592

7.  Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Authors:  J K Hennan; J Huang; T D Barrett; E M Driscoll; D E Willens; A M Park; L J Crofford; B R Lucchesi
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

8.  Attenuation of hyperalgesia in a rat model of neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist.

Authors:  Catherine M Cahill; Terence J Coderre
Journal:  Pain       Date:  2002-02       Impact factor: 6.961

9.  Increases in spinal vasoactive intestinal polypeptide and neuropeptide Y are not sufficient for the genesis of neuropathic pain in rats.

Authors:  Hee Jin Kim; Seung Keun Back; Junesun Kim; Backil Sung; Seung Kil Hong; Heung Sik Na
Journal:  Neurosci Lett       Date:  2003-05-15       Impact factor: 3.046

10.  Hyperalgesic effects of gamma-aminobutyric acid transporter I in mice.

Authors:  Jia-Hua Hu; Na Yang; Ying-Hua Ma; Xiao-Gang Zhou; Jie Jiang; Shu-Hui Duan; Zhen-Tong Mei; Jian Fei; Li-He Guo
Journal:  J Neurosci Res       Date:  2003-08-15       Impact factor: 4.164

View more
  3 in total

1.  Modulation of Exercise-Induced Muscle Damage, Inflammation, and Oxidative Markers by Curcumin Supplementation in a Physically Active Population: A Systematic Review.

Authors:  Diego Fernández-Lázaro; Juan Mielgo-Ayuso; Jesús Seco Calvo; Alfredo Córdova Martínez; Alberto Caballero García; Cesar I Fernandez-Lazaro
Journal:  Nutrients       Date:  2020-02-15       Impact factor: 5.717

2.  Low-molecular synthetic peptides with non-narcotic type of analgesia: comparative study and mechanism of analgesic activity.

Authors:  Arkady M Kotin; Maksim O Emelyanov; Oleg A Kotin
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

Review 3.  Phytochemistry, pharmacological activity, and potential health benefits of Gly cyrrhiza glabra.

Authors:  Md Kamrul Hasan; Iffat Ara; Muhammad Shafiul Alam Mondal; Yearul Kabir
Journal:  Heliyon       Date:  2021-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.